Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its participation in two major investor conferences in September 2024. The company will present overviews at the Wells Fargo 2024 Healthcare Conference in Boston on September 4 at 9:30 am ET, and the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on the same day at 1:05 pm ET.
Investors and interested parties can access live audio webcasts of both presentations through the Investors section of Alnylam's website at www.alnylam.com/events. Replays will be made available within 48 hours after each event, allowing those unable to attend live to catch up on the company's latest updates and strategies.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un leader nelle terapie RNAi, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2024. L'azienda presenterà panoramiche alla Wells Fargo 2024 Healthcare Conference a Boston il 4 settembre alle 9:30 am ET, e alla Morgan Stanley 22nd Annual Global Healthcare Conference a New York City lo stesso giorno alle 1:05 pm ET.
Investitori e parti interessate possono accedere alle webcasting audio dal vivo di entrambe le presentazioni attraverso la sezione Investors sul sito web di Alnylam all'indirizzo www.alnylam.com/events. Le registrazioni saranno disponibili entro 48 ore dopo ciascun evento, consentendo a coloro che non possono partecipare dal vivo di aggiornarsi sulle ultime novità e strategie dell'azienda.
Alnylam Pharmaceuticals (Nasdaq: ALNY), líder en terapias de RNAi, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2024. La compañía presentará informes en la Wells Fargo 2024 Healthcare Conference en Boston el 4 de septiembre a las 9:30 am ET, y en la Morgan Stanley 22nd Annual Global Healthcare Conference en Nueva York el mismo día a la 1:05 pm ET.
Los inversores y partes interesadas pueden acceder a las transmisiones en vivo de audio de ambas presentaciones a través de la sección de Inversores en el sitio web de Alnylam en www.alnylam.com/events. Las repeticiones estarán disponibles dentro de las 48 horas posteriores a cada evento, lo que permitirá a quienes no puedan asistir en vivo ponerse al día con las últimas actualizaciones y estrategias de la empresa.
알닐람 제약(주식 코드: ALNY)은 RNAi 치료 분야의 선두주자로서 2024년 9월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 9월 4일 오전 9시 30분 ET에 보스턴에서 열리는 웰스파고 2024 헬스케어 컨퍼런스와 같은 날 오후 1시 05분 ET에 뉴욕 시에서 열리는 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에서 개요를 발표할 예정입니다.
투자자와 관심 있는 분들은 Alnylam 웹사이트의 투자자 섹션을 통해 두 발표의 실시간 오디오 웹캐스트에 접속할 수 있습니다. 각 이벤트 후 48시간 이내에 재방송이 제공되어 실시간 참석이 불가능한 분들도 회사의 최신 업데이트와 전략에 대해 따라잡을 수 있습니다.
Alnylam Pharmaceuticals (Nasdaq: ALNY), un leader dans les thérapies par l’ARNi, a annoncé sa participation à deux grandes conférences pour investisseurs en septembre 2024. La société présentera des aperçus lors de la Wells Fargo 2024 Healthcare Conference à Boston le 4 septembre à 9h30 ET, et lors de la Morgan Stanley 22nd Annual Global Healthcare Conference à New York le même jour à 13h05 ET.
Les investisseurs et les parties intéressées peuvent accéder aux webcasts audio en direct des deux présentations via la section Investisseurs du site web d'Alnylam à l'adresse www.alnylam.com/events. Des rediffusions seront disponibles dans les 48 heures suivant chaque événement, permettant à ceux qui ne peuvent pas assister en direct de se tenir au courant des dernières mises à jour et stratégies de l’entreprise.
Alnylam Pharmaceuticals (Nasdaq: ALNY), ein führendes Unternehmen im Bereich RNAi-Therapeutika, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird Übersichtsvorträge auf der Wells Fargo 2024 Healthcare Conference in Boston am 4. September um 9:30 Uhr ET und auf der Morgan Stanley 22nd Annual Global Healthcare Conference in New York City am selben Tag um 13:05 Uhr ET halten.
Investoren und Interessierte können über den Bereich Investoren auf der Website von Alnylam unter www.alnylam.com/events auf die Live-Audio-Webcasts beider Präsentationen zugreifen. Wiederholungen werden innerhalb von 48 Stunden nach jeder Veranstaltung verfügbar gemacht, sodass diejenigen, die nicht live teilnehmen können, sich über die neuesten Updates und Strategien des Unternehmens informieren können.
- None.
- None.
-
Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 9:30 am ET in
Boston -
Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 1:05 pm ET in
New York City
A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828695871/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When and where is Alnylam (ALNY) presenting at the Wells Fargo 2024 Healthcare Conference?
What time is Alnylam's (ALNY) presentation at the Morgan Stanley Global Healthcare Conference in 2024?
How can investors access Alnylam's (ALNY) September 2024 investor conference presentations?
Will replays of Alnylam's (ALNY) September 2024 investor presentations be available?
